The Quantellect read.As of Nov 19, 2026, 5 active firms cover ProQR Therapeutics BV: 5 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. The target range is very wide, $3.00 to $10.00 (about 3.3x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $7.00 sits 548% above the current $1.08. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 4 to 5 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.15 next quarter toward $-0.45 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 active firms
Buy
Strong Buy00%
Buy5100%
Neutral00%
Sell00%
Strong Sell00%
Based on 5 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$7.00
+548.1% upside
Average target across 5 active firms as of Nov 19, 2026 vs $1.08 current
Highest Target$10.00
Average Target$7.00
Lowest Target$3.00
Detailed analyst forecasts for PRQR
Showing 1–5 of 5 named analysts shown · 5 active firms in the rating projection
As of Nov 19, 2026, 5 of 5 active firms rate PRQR a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
PRQR EPS & revenue forecast
EPS · NEXT QUARTER
$-0.15
Range $-0.19 – $-0.11 · 2 analysts · -0% YoY
Next period, 2 analysts expect ProQR Therapeutics BV to earn $-0.15 a share (range $-0.19 – $-0.11), versus $-0.15 a year earlier. Full-year consensus is $-0.45, growing to $-0.45 the year after.
REVENUE · NEXT QUARTER
$4.3M
Range $0 – $6.0M · 2 analysts · +81% YoY
Revenue is expected to reach $4.3M (range $0 – $6.0M), +80.8% year-over-year. Full-year consensus is $21.9M, rising to $18.2M next year.
Top analysts covering ProQR Therapeutics BV
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on PRQR.
#1
Jonathan Wolleben
JMP Securities · Rank #54
Buy
$8.00+640.7% to target
Overall win rate
43%
+ Follow
#2
Andrew Fein
HC Wainwright & Co. · Rank #73
Buy
$12.00+1011.1% to target
Overall win rate
45%
+ Follow
#3
Keay Nakae
Chardan Capital · Rank #130
Buy
$3.00+177.8% to target
Overall win rate
41%
+ Follow
#4
Andreas Argyrides
Oppenheimer · Rank #380
Buy
$9.00+733.3% to target
Overall win rate
41%
+ Follow
#5
GC
Gavin Clark-Gartner
Evercore ISI Group
Buy
$6.00+455.6% to target
Coverage
—
+ Follow
PRQR stock forecast FAQ
What is PRQR's average 12-month price target?+
The 5 active firms with a live target average $7.00 for ProQR Therapeutics BV over the next 12 months, ranging from a $10.00 high to a $3.00 low, as of Nov 19, 2026.
Is PRQR stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 5 active firms as of Nov 19, 2026, 5 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for PRQR?+
The Street-high target is $10.00 (Jones Trading), and the Street-low is $3.00 (Chardan Capital). The average of all 5 active-firm targets is $7.00.
How many active Wall Street firms cover PRQR?+
5 active firms have a recognized rating on ProQR Therapeutics BV as of Nov 19, 2026, and 5 active firms carry a live 12-month price target.
Who is the most accurate analyst covering PRQR?+
Among analysts who currently cover PRQR, Jonathan Wolleben of JMP Securities has the strongest overall Quantellect track record (Rank #54). Their current call is Buy with a $8.00 target.
What is ProQR Therapeutics BV's projected EPS for next quarter?+
The consensus estimate is $-0.15 per share (range $-0.19 – $-0.11) across 2 analysts. Full-year EPS is projected at $-0.45, rising to $-0.45 the following year.
How much revenue is ProQR Therapeutics BV expected to report next quarter?+
Consensus revenue is $4.3M (range $0 – $6.0M). Full-year revenue is projected at $21.9M, growing to $18.2M next year.
Have analysts been upgrading or downgrading PRQR lately?+
As of Nov 19, 2026, 5 of 5 active firms rate PRQR a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their PRQR calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.